Sacituzumab Tirumotecan for Pancreatic Cancer
NCT07561463
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
DRUG:
Sacituzumab tirumotecan
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences